Michael Barbella, Managing Editor11.15.22
Researchers at NuraLogix, a developer of contactless health monitoring through its patented Transdermal Optical Imaging (TOI) technology, is adding the ability to perform metabolic and blood biomarker health risk assessments for various chronic conditions to its Anura platform. As a first for video-based contactless health monitoring, the new capabilities add to the existing health and wellness measurements* Anura can assess from a 30-second video selfie, including the ability to accurately measure blood pressure.
NuraLogix's technology allows third-party clients such as health providers, product developers, insurance companies, and wellness programs to help consumers better manage their physical and mental health. Anura is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments. The expansion of its capabilities to assess HbA1c and monitor fasting glucose, as well as assess risk of type 2 diabetes, hypertension, and hypertriglyceridemia will join the existing cardiovascular disease risk assessments, including 10-year predictions of risk of death from heart attack or stroke.
"Following years of research and development, we are excited to share the expanded capabilities of the Anur platform. Our research models have been proven to predict whether a subject's HbA1c is greater than 5.7%, or their Fasting Blood Glucose is greater than 5.5 mmol/L, to a clinically accurate level," said Dr. Keith Thompson, chief medical officer at NuraLogix. "The ability to assess health with just a look into everyday, readily available consumer devices is a game changer for the healthcare industry. Using ubiquitous devices, Anura has the potential to accelerate the adoption of solutions for the early detection of chronic diseases, expand health equity and access to underserved populations while dramatically decreasing costs of care."
How It Works
NuraLogix delivers contactless health monitoring via its Anura platform that combines data gathered through its TOI technology, a novel form of Remote Photoplethysmography (rPPG). Developed with data from more than 40,000 patients with multiple conditions, NuraLogix's research on these predicted models has been tested and published in numerous peer-reviewed journals worldwide. Anura uses a conventional video camera to extract facial blood flow information combined with sophisticated AI model analysis in the cloud that extrapolates health information from the pattern of facial blood flows. Results are delivered within its intuitive app, showing information on over 30 health parameters* such as heart rate, breathing rate, and cuffless blood pressure, and providing health risk assessments for some of the most prevalent chronic conditions. This includes type 2 diabetes, hypertension, cardiovascular disease, and mental health.
Flexible Modular Delivery
NuraLogix's Anura includes capabilities for investigational use and go-to-market solutions to allow its customers (companies such as NTT Data, Bupa Group, HSBC, AIA, and FWD) to build flexible bespoke programs to meet the needs of their customers by combining various Anura capabilities including:
With the ability to be delivered as a branded or white label solution, NuraLogix is paving the way to a world where health vitals are continually monitored with just a look at a smartphone, bathroom mirror, TV screen, or kiosk—transforming the way chronic diseases are identified, managed, and prevented.
NuraLogix is the creator of the world's first contactless blood pressure measurement technology. The company's patented Transdermal Optical Imaging (TOI) technology can measure more than 30 health and wellness parameters using a conventional video camera to extract facial blood flow information from the human face. This is demonstrated in the company's Anura app.
*In the United States, some features of this product are for investigational use only. The performance characteristics of the product have not been established.
NuraLogix's technology allows third-party clients such as health providers, product developers, insurance companies, and wellness programs to help consumers better manage their physical and mental health. Anura is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments. The expansion of its capabilities to assess HbA1c and monitor fasting glucose, as well as assess risk of type 2 diabetes, hypertension, and hypertriglyceridemia will join the existing cardiovascular disease risk assessments, including 10-year predictions of risk of death from heart attack or stroke.
"Following years of research and development, we are excited to share the expanded capabilities of the Anur platform. Our research models have been proven to predict whether a subject's HbA1c is greater than 5.7%, or their Fasting Blood Glucose is greater than 5.5 mmol/L, to a clinically accurate level," said Dr. Keith Thompson, chief medical officer at NuraLogix. "The ability to assess health with just a look into everyday, readily available consumer devices is a game changer for the healthcare industry. Using ubiquitous devices, Anura has the potential to accelerate the adoption of solutions for the early detection of chronic diseases, expand health equity and access to underserved populations while dramatically decreasing costs of care."
How It Works
NuraLogix delivers contactless health monitoring via its Anura platform that combines data gathered through its TOI technology, a novel form of Remote Photoplethysmography (rPPG). Developed with data from more than 40,000 patients with multiple conditions, NuraLogix's research on these predicted models has been tested and published in numerous peer-reviewed journals worldwide. Anura uses a conventional video camera to extract facial blood flow information combined with sophisticated AI model analysis in the cloud that extrapolates health information from the pattern of facial blood flows. Results are delivered within its intuitive app, showing information on over 30 health parameters* such as heart rate, breathing rate, and cuffless blood pressure, and providing health risk assessments for some of the most prevalent chronic conditions. This includes type 2 diabetes, hypertension, cardiovascular disease, and mental health.
Flexible Modular Delivery
NuraLogix's Anura includes capabilities for investigational use and go-to-market solutions to allow its customers (companies such as NTT Data, Bupa Group, HSBC, AIA, and FWD) to build flexible bespoke programs to meet the needs of their customers by combining various Anura capabilities including:
- Physiological Health Vitals/Indexes: blood pressure, cardiac workload, heart rate, breathing/respiratory rate, irregular heart rate, heart rate variability, facial skin age
- Mental Health/Risk Assessments: mental stress, depression health risk, anxiety health risk
- Physiological Health/Risk Assessments: T2 Diabetes risk assessment, fatty liver disease risk assessment, HbA1c risk assessment, fasting blood glucose risk assessment, cardiovascular disease risks (10-year prediction of risk of death from heart attack or stroke), hypertension risk, hypercholesterolemia, hypertriglyceridemia
With the ability to be delivered as a branded or white label solution, NuraLogix is paving the way to a world where health vitals are continually monitored with just a look at a smartphone, bathroom mirror, TV screen, or kiosk—transforming the way chronic diseases are identified, managed, and prevented.
NuraLogix is the creator of the world's first contactless blood pressure measurement technology. The company's patented Transdermal Optical Imaging (TOI) technology can measure more than 30 health and wellness parameters using a conventional video camera to extract facial blood flow information from the human face. This is demonstrated in the company's Anura app.
*In the United States, some features of this product are for investigational use only. The performance characteristics of the product have not been established.